What is Dexcom?
Dexcom, Inc. is a leading innovator in medical technology, specializing in the development and manufacturing of continuous glucose monitoring (CGM) systems. These advanced devices provide individuals with diabetes real-time glucose data, empowering them to manage their health more effectively. The company's commitment to accuracy, innovation, and enhancing the quality of life for its users positions it at the forefront of diabetes care advancements worldwide. Dexcom's focus on improving patient outcomes through technology has solidified its reputation in the healthcare industry.
How much funding has Dexcom raised?
Dexcom has raised a total of $457.7M across 5 funding rounds:
Series C
$30M
Series D
$22.5M
Stock Offering
$50.6M
Share Placement
$350M
Series B
$4.6M
Series C (2002): $30M with participation from INVESCO, Windamere Venture Partners, Kauffman Fund, St. Paul Venture Capital, Fog City Fund, Canaan Partners, and RWI Investments
Series D (2005): $22.5M led by The Vertical Group, Fog City Fund, St. Paul Venture Capital, Warburg Pincus, Federated Kaufmann Fund, RWI Group, and Canaan Partners
Stock Issuance/Offering (2005): $50.6M supported by Undisclosed
Share Placement (2017): $350M featuring Undisclosed
Series B (2020): $4.6M backed by Beta Bionics
Key Investors in Dexcom
The Vertical Group
The Vertical Group is an investment bank providing strategic advice and capital raising services to corporations, governments, and organizations across various sectors. They focus on helping clients grow by extending resources and fostering partnerships.
Warburg Pincus
Warburg Pincus is a global private equity firm specializing in growth investing, supporting investors and management teams in building long-term value across diverse industries and geographies.
Canaan Partners
Canaan is an early-stage venture capital firm investing in technology and healthcare companies, from seed through growth stages, with a focus on enterprise software, fintech, biopharma, and digital health.
What's next for Dexcom?
With a significant influx of capital, Dexcom is poised for accelerated growth and continued technological advancement. The recent major strategic investment suggests a strong validation of the company's market position and future potential. This funding is likely to be directed towards enhancing research and development for next-generation CGM devices, expanding manufacturing capabilities to meet growing global demand, and potentially exploring new market segments or strategic partnerships. Dexcom's trajectory indicates a strong focus on solidifying its leadership in diabetes management technology and further improving the lives of millions worldwide.
See full Dexcom company page
